Cargando…

The Antiresorptive Effect of GIP, But Not GLP‐2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study

Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐2 (GLP‐2) are gut hormones secreted postprandially. In healthy humans, both hormones decrease bone resorption accompanied by a rapid reduction in parathyroid hormone (PTH). The aim of this study was to investigate whether t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skov‐Jeppesen, Kirsa, Hepp, Nicola, Oeke, Jannika, Hansen, Morten Steen, Jafari, Abbas, Svane, Maria Saur, Balenga, Nariman, Olson, John A, Frost, Morten, Kassem, Moustapha, Madsbad, Sten, Beck Jensen, Jens‐Erik, Holst, Jens Juul, Rosenkilde, Mette Marie, Hartmann, Bolette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338760/ https://www.ncbi.nlm.nih.gov/pubmed/33852173 http://dx.doi.org/10.1002/jbmr.4308

Ejemplares similares

Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment
por: Schiellerup, Sine Paasch, et al.
Publicado: (2019)

A Pilot Study Showing Acute Inhibitory Effect of GLP‐1 on the Bone Resorption Marker CTX in Humans
por: Nissen, Anne, et al.
Publicado: (2019)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans
por: Kuhre, Rune E., et al.
Publicado: (2014)

Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays
por: Boer, Geke Aline, et al.
Publicado: (2021)

Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma
por: Asmar, Ali, et al.
Publicado: (2020)

The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection
por: Lindquist, Peter, et al.
Publicado: (2022)

Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion
por: Saltiel, Monika Y., et al.
Publicado: (2017)

GIP-induced vasodilation in human adipose tissue involves capillary recruitment
por: Asmar, Meena, et al.
Publicado: (2019)

The anorexic hormone Peptide YY(3–36) is rapidly metabolized to inactive Peptide YY(3–34) in vivo
por: Toräng, Signe, et al.
Publicado: (2015)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
por: Sparre‐Ulrich, A H, et al.
Publicado: (2015)

Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss()
por: Holst, Jens Juul, et al.
Publicado: (2018)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long‐term impairment of the GIP system
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2019)

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men
por: Hagemann, Christoffer A., et al.
Publicado: (2022)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women
por: Otten, Julia, et al.
Publicado: (2019)

N‐terminal alterations turn the gut hormone GLP‐2 into an antagonist with gradual loss of GLP‐2 receptor selectivity towards more GLP‐1 receptor interaction
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2022)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
por: Hedbäck, Nora, et al.
Publicado: (2022)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2019)

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake
por: Bojsen-Møller, Kirstine Nyvold, et al.
Publicado: (2023)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

The Role of Incretins on Insulin Function and Glucose Homeostasis
por: Holst, Jens Juul, et al.
Publicado: (2021)

Acute effects of glucagon‐like peptide‐1, GLP‐1(9–36 amide), and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers
por: Bremholm, Lasse, et al.
Publicado: (2017)

Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
por: Asmar, Meena, et al.
Publicado: (2010)

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
por: Asmar, Ali, et al.
Publicado: (2017)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

GLP1 and GIP are involved in the action of synbiotics in broiler chickens
por: Kolodziejski, Pawel Antoni, et al.
Publicado: (2018)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor
por: Hansen, L S, et al.
Publicado: (2016)

The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion
por: Hjørne, Anna Pii, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v1pmrra2fn7eu4rd4rp4gathnk